Combination percutaneous cryotherapy and iodine-125 seed implantation for unresectable malignant thymoma: Experience in 19 patients

详细信息    查看全文

• 作者：Zhikai Zhang ; Binghui Wu ; Lizhi Niu ; Feng Mu ; Jibing Chen ; Jialiang Li ; Jiansheng Zuo ; Kecheng Xu
• 关键词：Malignant thymoma ; Percutaneous cryoablation ; Progression-free survival ; Myasthenia gravis
• 刊名：Cryobiology
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：67
• 期：2
• 页码：170-174
• 全文大小：999 K

文摘

Thymomas are the most common tumors of the mediastinum. These tumors often compress vital mediastinal organs and severely impact the quality of life of thymoma patients. To avoid the side effects of chemoradiotherapy, some patients with unresectable malignant thymomas have opted to undergo cryotherapy in our hospital. We reviewed the cryosurgery, nursing and follow-up records of our hospital for the past 8 years, and evaluated the safety and efficiency of cryotherapy in 19 patients with unresectable malignant thymomas. No severe complications involving the vital organs surrounding the tumor occurred during or after cryosurgery. The most common side effect was pleural effusion, which occurred in 11 patients and healed after drainage within 1 week. Cough, mediastinal and pericardial effusions, pneumothorax, mild fever and chest tightness also occurred and resolved 1 week after symptomatic treatment. Since our patients had high KPS scores and mild myasthenia gravis symptoms before the treatment, myasthenia gravis did not occur after the treatment. The progression-free survival of the patients was 14-29 months (median, 18 months), and did not differ between patients with large tumors and those with small tumors (P = 0.6753). In conclusion, cryotherapy is a safe and efficient method for the treatment of unresectable malignant thymoma.